Key result
General anesthesia linked to ~32% higher 30-day mortality vs local anesthesia in PAH.
Why the study?
Patients with pulmonary arterial hypertension face substantial perioperative morbidity and mortality, but the optimal anesthetic strategy (general vs local anesthesia) and its impact on outcomes remain poorly defined.
Does general anesthesia increase mortality compared to local anesthesia in adult patients with pulmonary arterial hypertension undergoing procedures?
Cohort (n=41,694)
Yes
Does general anesthesia increase mortality compared to local anesthesia in adult patients with pulmonary arterial hypertension undergoing procedures?
Effect estimate: HR 1.32
Absolute Event Rate: 4.6% vs 3.5%
p-value: p=<0.001
In patients with pulmonary arterial hypertension, general anesthesia is associated with a higher risk of mortality and postoperative vasopressor support up to 6 months compared to local anesthesia.
General anesthesia was associated with higher all-cause mortality; leaves open confounding and requires randomized trials before practice change.
Rationale Patients with Pulmonary Arterial hypertension (PAH) face a substantial risk of perioperative morbidity and mortality. The optimal anesthetic strategy, general anesthesia (GA) versus local anesthesia (LA), and its impact on short and long-term outcomes remain poorly defined. This study aimed to compare postoperative outcomes at multiple time points between these two anesthetic modalities in a large, real-world cohort of patients with PAH. Methods A retrospective cohort study was conducted using the TriNetX global federated health research network. We identified adult patients with a diagnosis of primary or secondary PAH, confirmed by the use of specific PAH-targeted medications, who underwent a procedure with either GA or LA. To control for baseline differences, the cohorts were balanced using 1:1 propensity-score matching. Key outcomes, including all-cause mortality, right heart failure exacerbation, vasopressor use, hospital readmission, and initiation of IV prostacyclin, were assessed at 30, 90, and 180 days post-procedure. Results We identified an initial cohort of 21,283 PAH patients receiving general anesthesia (GA) and 24,890 receiving local anesthesia (LA). After 1:1 propensity-score matching, 20,847 patients remained in each cohort. General anesthesia was associated with a significantly higher risk of all-cause mortality at all time points: at 30 days (4.6% vs. 3.5%; HR 1.32; p < 0.001), at 90 days (7.3% vs. 6.1%; HR 1.215; p < 0.001), and at 180 days (9.9% vs. 8.9%; HR 1.13; p < 0.001). The requirement for postoperative vasopressor support was also significantly higher in the GA group at 30 days (3.9% vs. 3.5%; HR 1.13; p = 0.026), 90 days (HR 1.15; p = 0.004), and 180 days (HR 1.1; p = 0.02). At all evaluated time points, there were no significant differences in the rates of right heart failure exacerbation, all-cause readmission, or new IV prostacyclin use. Conclusion In this large, propensity-score matched analysis of patients with Pulmonary Arterial Hypertension, general anesthesia was associated with a higher risk of mortality through 6 months compared to local anesthesia. This finding suggests that, when clinically feasible for the planned procedure, selecting a local or regional anesthetic technique may be a critical strategy to improve long-term survival in this high-risk patient population. This abstract is funded by: none
No takes yet. Share an insight, caveat, or question.
Tated et al. (2026) conducted a cohort in Pulmonary Arterial Hypertension (n=41,694). General anesthesia vs. Local anesthesia was evaluated on All-cause mortality at 30 days (HR 1.32, p=<0.001). General anesthesia was associated with a significantly higher risk of 30-day all-cause mortality compared to local anesthesia in patients with PAH (4.6% vs. 3.5%; HR 1.32; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: